Cytogen to license prostate test technology:
This article was originally published in Clinica
Cytogen plans to obtain an exclusive, worldwide licence to Molecular Staging's Rolling Circle Amplification Technology (RCAT) to develop in vitro tests for prostate specific membrane antigen (PSMA) and prostate specific antigen (PSA). According to Princeton, New Jersey-based Cytogen, serum PSMA is increased in prostate cancer, but appears to be unaffected by other miscellaneous events, unlike PSA. Cytogen plans to use the RCAT technology to develop a PSMA and PSA test for prostate cancer and hopes to have an assay for clinical study by mid-2000.
You may also be interested in...
Abbott reported almost 28% revenue growth in the fourth quarter led by the exploding demand for COVID-19 tests and continued success of its FreeStyle Libre continuous glucose monitor.
While representing a smaller population, the ACTIVATE-T trial targeted patients seen as having greater unmet need.
As a freshman member on the US House Energy and Commerce Committee, former St. Jude Medical exec Rep. Angie Craig can help shape future health care, cybersecurity bills.